Attenuation of sepsis-related immunoparalysis by continuous venovenous hemofiltration in experimental porcine pancreatitis

被引:164
作者
Yekebas, EF
Eisenberger, CF
Ohnesorge, H
Saalmüller, A
Elsner, HA
Engelhardt, M
Gillesen, A
Meins, J
The, M
Strate, T
Busch, C
Knoefel, WT
Bloechle, C
Izbicki, JR
机构
[1] Univ Hamburg, Klinikum Eppendorf, Allgemeinchirurg Abt, Dept Surg, D-20246 Hamburg, Germany
[2] Univ Hamburg, Hosp Eppendorf, Dept Anesthesiol, Hamburg, Germany
[3] Univ Hamburg, Hosp Eppendorf, Dept Med Microbiol & Immunol, Hamburg, Germany
[4] Fed Res Ctr Virus Dis Anim, Tuebingen, Germany
关键词
swine; physiopathology of pancreatitis; mediators of inflammation; tumor-necrosis-factor; cytokines; sepsis syndrome; immunoparalysis; immunology of monocytes; immunology of neutrophils; bacterial translocation;
D O I
10.1097/00003246-200107000-00021
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Objectives: In light of evidence suggesting that hemofiltration favorably influences septic diseases by removing sepsis mediators, the impact of different modalities of continuous veno-venous hemofiltration (CVVH) on outcome and immunologic derangements in porcine pancreatogenic sepsis was evaluated. Design:Randomized, controlled intervention trial, Subjects: Forty-eight minipigs of either sex, Interventions: Pancreatitis was induced by intraductal injection of sodium taurocholate (4%, 1 mL/kg body weight [BW]) and enterokinase (2 U/kg BW), Animals were allocated either to untreated controls-group 1-or to one of three treatment groups-group 2: low-volume CVVH (20 mL/kg BW), no change of hemofilters; group 3: law-volume CVVH, filters changed every 12 hrs; and group 4: high-volume CVVH (100 mL/kg BW), filters changed every 12 hrs. Survival represented the major parameter of the study. Serum cytokine levels, sepsis-related down-regulation of major histocompatibility complex II and CD14 expression on leukocytes, bacterial translocation, and endotoxemia were further parameters evaluated in the study. Measurements and Main Results: High-volume CVVH combined with periodic fiber change was significantly superior compared with less intensive treatment modalities (low-volume CVVH, no filter change) in sepsis protection. Long-term survival (> 60 hrs) was found in 67% of group 4 and 33% of group 3 animals (p < .05), whereas in controls and group 2 no animal survived. CVVH ameliorated the initial serum tumor necrosis factor-a! response and prevented sepsis-induced in vivo endotoxin hyporesponsiveness. Down-regulation of major histocompatibility complex II and CD14 expression on monocytes was significantly improved by CVVH, improved oxidative burst and phagocytosis capacity in polymorphonuclear leukocytes suggested that leukocyte function was stabilized by CVVH. Also, CVVH significantly reduced bacterial translocation and endotoxemia, Conclusions: Hemofiltration reversed sepsis-induced immuno-paralysis in a porcine model of bile acid-induced pancreatitis. Implications for human pancreatitis must be validated in prospective, clinical protocols.
引用
收藏
页码:1423 / 1430
页数:8
相关论文
共 33 条
[1]  
[Anonymous], INTENS CARE MED
[2]   INTERLEUKIN-10 PROTECTS MICE AGAINST STAPHYLOCOCCAL-ENTEROTOXIN B-INDUCED LETHAL SHOCK [J].
BEAN, AGD ;
FREIBERG, RA ;
ANDRADE, S ;
MENON, S ;
ZLOTNIK, A .
INFECTION AND IMMUNITY, 1993, 61 (11) :4937-4939
[3]   CONTINUOUS VENOVENOUS HEMOFILTRATION WITH DIALYSIS REMOVES CYTOKINES FROM THE CIRCULATION OF SEPTIC PATIENTS [J].
BELLOMO, R ;
TIPPING, P ;
BOYCE, N .
CRITICAL CARE MEDICINE, 1993, 21 (04) :522-526
[4]   MODULATION OF THE ENDOTOXIN RECEPTOR (CD14) IN SEPTIC PATIENTS [J].
BIRKENMAIER, C ;
HONG, YS ;
HORN, JK .
JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE, 1992, 32 (04) :473-479
[5]  
BLINZLER L, 1991, CONTRIB NEPHROL, V93, P234
[6]   TOWARD AN EPIDEMIOLOGY AND NATURAL-HISTORY OF SIRS (SYSTEMIC INFLAMMATORY RESPONSE SYNDROME) [J].
BONE, RC .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1992, 268 (24) :3452-3455
[7]   AMERICAN-COLLEGE OF CHEST PHYSICIANS SOCIETY OF CRITICAL CARE MEDICINE CONSENSUS CONFERENCE - DEFINITIONS FOR SEPSIS AND ORGAN FAILURE AND GUIDELINES FOR THE USE OF INNOVATIVE THERAPIES IN SEPSIS [J].
BONE, RC ;
BALK, RA ;
CERRA, FB ;
DELLINGER, RP ;
FEIN, AM ;
KNAUS, WA ;
SCHEIN, RMH ;
SIBBALD, WJ ;
ABRAMS, JH ;
BERNARD, GR ;
BIONDI, JW ;
CALVIN, JE ;
DEMLING, R ;
FAHEY, PJ ;
FISHER, CJ ;
FRANKLIN, C ;
GORELICK, KJ ;
KELLEY, MA ;
MAKI, DG ;
MARSHALL, JC ;
MERRILL, WW ;
PRIBBLE, JP ;
RACKOW, EC ;
RODELL, TC ;
SHEAGREN, JN ;
SILVER, M ;
SPRUNG, CL ;
STRAUBE, RC ;
TOBIN, MJ ;
TRENHOLME, GM ;
WAGNER, DP ;
WEBB, CD ;
WHERRY, JC ;
WIEDEMANN, HP ;
WORTEL, CH .
CRITICAL CARE MEDICINE, 1992, 20 (06) :864-874
[8]  
BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77
[9]   Decreased interleukin-2 production in murine acute pancreatitis: Potential for immunomodulation [J].
Curley, P ;
Nestor, M ;
Collins, K ;
Saporoschetz, I ;
Mendez, M ;
Mannick, JA ;
Rodrick, ML .
GASTROENTEROLOGY, 1996, 110 (02) :583-588
[10]  
GEBHARDT C, 1994, CHIRURG, V65, P33